Quarterly ResultMay 7, 2026, 04:54 PM
Amphastar Q1 Net Income Down 74.7% to $6.42M; EPS $0.14
AI Summary
Amphastar Pharmaceuticals reported a significant decline in profitability for Q1 2026, with net income falling by 74.7% to $6.42 million and diluted EPS decreasing to $0.14. This occurred despite a slight increase in net revenues to $171.17 million. The company experienced a substantial rise in cost of revenues and research and development expenses, impacting gross profit and operating income. However, net cash provided by operating activities increased by 36.4% year-over-year.
Key Highlights
- Net income decreased 74.7% to $6.42 million from $25.29 million YoY.
- Diluted EPS fell 72.5% to $0.14 from $0.51 YoY.
- Net revenues slightly increased 0.38% to $171.17 million from $170.53 million YoY.
- Gross profit declined 17.5% to $70.32 million from $85.25 million YoY.
- Research and development expenses rose 33.0% to $26.74 million YoY.
- Net cash from operating activities increased 36.4% to $47.84 million YoY.
- Purchased $29.49 million in treasury stock, up from $11.00 million YoY.
- Total assets grew to $1.65 billion from $1.63 billion at Dec 31, 2025.
Price Impact
More from AMPH